Erector Spinae Plane Block Versus Serratus Plane Block for Breast Surgery
NCT ID: NCT03538483
Last Updated: 2019-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2017-12-01
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Video Assisted Thoracoscopic Surgery
NCT03538496
Different Volumes of Erector Spinae Plane Block for Breast Surgery
NCT05232084
Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery
NCT04218149
Serratus Plane Block For Breast Reduction Surgery
NCT02930733
The Effects of Erector Spinae Plane Block on Pain Scores in Unilateral Breast Cancer Surgery
NCT07134933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ultrasound guided serratus plane block
Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
Bupivacaine Hcl 0.25% Inj
30 ml %0,25 bupivacaine
ultrasound guided erector spinae plane block
Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
Bupivacaine HCl Inj 0.25%
20 ml %0,25 bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacaine Hcl 0.25% Inj
30 ml %0,25 bupivacaine
Bupivacaine HCl Inj 0.25%
20 ml %0,25 bupivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergoing breast cancer surgery
* 18-65 years
Exclusion Criteria
* bleeding disorders
* renal or hepatic insufficiency
* patients on chronic non-steroidal anti-inflammatory medications
* emergency cases
* coagulopathy
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ataturk University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali Ahiskalioglu
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ataturk University
Erzurum, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUTFANESTHESIA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.